ArticleBlood2009
VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy.
Article in Blood, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 2 syntheses or guidelines pooled it, 152 citations in OpenAlex.
- Guideline
- Recommendations of the SFH (French Society of Haematology) for the diagnosis, treatment and follow-up of hairy cell leukaemia.Annals of hematology · 2014Guideline
- Long term follow-up of a phase II study of cladribine with concurrent rituximab with hairy cell leukemia variant.Blood advances · 2021Trial
- Prospective long-term follow-up after first-line subcutaneous cladribine in hairy cell leukemia: a SAKK trial.Blood advances · 2020Trial
- Identification of the BRAF V600E mutation in Japanese patients with hairy cell leukemia and related diseases using a quenching probe method.International journal of hematology · 2018Trial
- Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial.British journal of haematology · 2016Trial
- Trial
- Classic Hairy Cell Leukemia and Related Disorders: An Updated Review of Molecular Features and Personalized Therapies.Journal of personalized medicine · 2026Review
- Complete Response in Hairy Cell Leukemia to Anti-CD22 CAR T-Cell Therapy.JCO precision oncology · 2025Article
- Observational
- COVID-19 vaccination in patients with classic and variant hairy cell leukemia.Blood neoplasia · 2024Article
- Untangling hairy cell leukaemia (HCL) variant and other HCL-like disorders: Diagnosis and treatment.Journal of cellular and molecular medicine · 2024Review
- Frequent CDKN2B/P15 and DAPK1 methylation in duodenal follicular lymphoma is related to duodenal reactive lymphoid hyperplasia.Journal of clinical and experimental hematopathology : JCEH · 2024Article
- Fucosyltransferase 3 and 8 promote the metastatic capacity of cancer stem-like cells via CD15s and E-cadherin in esophageal cancer.Iranian journal of basic medical sciences · 2024Article
- COVID-19 in patients with classic and variant hairy cell leukemia.Blood advances · 2023Article
- Hairy cell leukaemia with unusual BRAF mutations.Journal of cellular and molecular medicine · 2023Article
- Allogeneic hematopoietic cell transplant for hairy cell leukemia: EBMT experience.Haematologica · 2023Article
- The protective role of the microenvironment in hairy cell leukemia treatment: Facts and perspectives.Frontiers in oncology · 2023Review
- Hairy Cell Leukemia (HCL) and HCL Variant: Updates and Spotlights on Therapeutic Advances.Current oncology reports · 2022Review
- Purine nucleoside analogs plus rituximab are an effective treatment choice for hairy cell leukemia-variant.Annals of hematology · 2022Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Hairy cell leukemia variant (HCLv) presents with high disease burden, lack of typical antigens like CD25, and poor response to standard treatments like cladribine. Occasionally, patients with classic HCL respond poorly. Clinical and molecular features of HCL and HCLv has not been compared. Rearrangements expressing immunoglobulin VH chain were sequenced, including 22 from 20 patients with HCLv and 63 from 62 patients with classic HCL. Most patients were seeking relapsed/refractory trials, representing a poor-prognosis population. VH4-34, a gene commonly used in autoimmune disorders, was observed in 8 (40%) HCLv and 6 (10%) classic (P = .004) HCL patients. Compared with 71 VH4-34(-) rearrangements, 14 VH4-34(+) rearrangements were more frequently (P < .001) unmutated, defined as greater than 98% homologous to germline sequence. VH4-34(+) patients had greater white blood cell counts at diagnosis (P = .002), lower response rate (P < .001) and progression-free survival (P = .007) after initial cladribine, and shorter overall survival from diagnosis (P < .001). Response and survival were more closely related to VH4-34 status than to whether or not patients had HCLv. VH4-34(+) HCL is an important disorder that only partly overlaps with the previously described HCLv. Response to initial single-agent cladribine therapy is suboptimal; these patients should be considered for alternative approaches, including antibody-related therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.